Geiser Pharma is visited by Europa Press for being selected as SME of the year of Navarre
29 de March de 2021
Flurbiprofen lozenges honey&mint and lemon flavours, new products in Geiser Pharma
23 de August de 2022
CEO INSIGHTS
Written by Veronica Madrid
We leave a hard and challenging year behind, a year in which we have suffered a great impact due to the decrease in the supply of our main products based on cough and cold relief. A year in which we have been able to learn great lessons, a year that has strengthened the values and pillars of our company, reinforcing our flexibility and creativity and that has let us implement several plans and processes that will undoubtedly set the course of our near future.
This has only been possible thanks to the great and full dedicated team that builds up Geiser Pharma from the shareholders, who have opted to continue investing in people and projects despite the difficulties caused by the pandemic, to each person in my team who has fought every day to reach the goals and to satisfy our customers’ requirements.
Special thanks also to our suppliers, for their flexibility and for managing and getting used to our urgent requests, and to our customers for trusting us every day in spite of the situation; this has allowed us to sign 34 new contracts and close 2 strategic alliances within this period.
Now, it is time for us to put all our enthusiasm and willingness to work together in order to reach the goals we have set out in our new strategic plan for the coming years 2022-2025. Geiser Pharma has now a lot of incredible and exciting challenges and we certainly count on all of you.
Thank you for trusting Geiser Pharma.
2021 KEY ACHIEVEMENTS
We feel fortunate to close 2021 with all of you. We are grateful to our team for their engagement and to our clients and suppliers for their continuous trust and cooperation.
We will keep improving, but meanwhile we present you our 2021 key facts:
34
LICENSE AND SUPPLY AGREEMENTS
45
COUNTRIES (OUR FOOTPRINT)
15
LAUNCHES
3
NEW DEVELOPMENTS STARTED
2
NEW CONTRACT DEVELOPMENTS
48
NEW MA GRANTED
68
PRODUCTS UNDER REGISTRATION
ELEVATE WITH OUR PRODUCTS
GUMS WITH BENZOCAINE AND CHLORHEXIDINE
We are pleased to be able to offer you this innovative drug delivery system that brings added-value thanks to its enjoyable sensory experience and efficient delivery system.
Coated chewing gums tablets with 5 mg of Benzocaine and 5 mg Chlorhexidine have been developed to relief mild buccopharyngeal infections with pain for adults over 6 years.
Its high quality is ensured thanks to our strategic partner leader in gum base, the ingredient that distinguishes chewing and bubble gum from all other products.
This already approved product in Europe will differentiate yourself!
LOZENGES WITH BENZYDAMINE AND CETYLPIRIDINIUM
With 13 years of experience, Geiser Pharma has successfully completed the development of several drugs and it continues being commited with the development on new ones that could broad the portfolio of our clients.
Our huge experience in the development and the supply of cough&cold lozenges in more than 22 countries leads us to develop this product with triple action that relieves sore throat thanks to Benzydamine (3 mg) which has anti-inflammatory and analgesic properties and Cetylpiridinium (1 mg) that eliminates the cause of infection.
Our aim is to help you build your strong OTC portfolio.
Sign up here to receive our future newsletters: http://eepurl.com/hRezSr
